Favourable outcome of patients with breast cancer brain metastases treated with dual HER2 blockade of trastuzumab and pertuzumab

Favourable outcome of patients with breast cancer brain metastases treated with dual HER2 blockade of trastuzumab and pertuzumab

Background: Dual human epidermal growth factor receptor 2 (HER2) blockade with trastuzumab and pertuzumab (TP) is a standard therapy of metastatic and localized HER2-positive breast cancer (BC), but its activity in breast cancer brain metastases (BCBM) is unknown. Methods: Patients with HER2-positiv...

Full description

Bibliographic Details
Main Authors: Elisabeth Sophie Bergen, Amelie Binter, Angelika Martina Starzer, Gerwin Heller, Barbara Kiesel, Kristina Tendl-Schulz, Zsuzsanna Bago-Horvath, Julia Furtner, Johannes Leitner, Ruth Exner, Florian Fitzal, Karin Dieckmann, Georg Widhalm, Matthias Preusser, Anna Sophie Berghoff, Rupert Bartsch
Format: Article
Language:English
Published: SAGE Publishing 2021-04-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359211009002

Internet

https://doi.org/10.1177/17588359211009002

Similar Items